A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2018

A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine

Dates et versions

hal-02143656 , version 1 (29-05-2019)

Identifiants

Citer

L. Seguin, M. Chaffanet, R. Sabatier, A. Jose, S. Garnier, et al.. A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine. Annals of Oncology, 2018, 29 (6), ⟨10.1093/annonc/mdy314.030⟩. ⟨hal-02143656⟩

Collections

CNRS UNIV-AMU CRCM
13 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More